Oral Medium-Dosed Metoclopramide versus Placebo as Highly Effective Antiemetic Prophylaxis in In- and Outpatients on Noncisplatin Chemotherapy
| Autor: | H J Hausleiter, R. Saller, C. Vogt, G. Achtert, D. Hellenbrecht, P. Brockmann |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adult
Cancer Research Lung Neoplasms Adolescent Metoclopramide Vomiting medicine.drug_class medicine.medical_treatment Administration Oral Placebo Placebos Double-Blind Method Antineoplastic Combined Chemotherapy Protocols Outpatients Humans Medicine Antiemetic Aged Inpatients Xeroderma Pigmentosum Chemotherapy Dose-Response Relationship Drug business.industry Lymphoma Non-Hodgkin General Medicine Middle Aged Regimen Oncology Anesthesia Toxicity Cisplatin medicine.symptom business Complication medicine.drug |
| Zdroj: | Oncology. 50:81-85 |
| ISSN: | 1423-0232 0030-2414 |
| DOI: | 10.1159/000227153 |
| Popis: | The antiemetic effect of oral medium-dosed metoclopramide (MCL, 3.5 mg/kg b.w./cycle) and placebo for chemotherapy-induced emesis of a noncisplatin regimen was assessed for inpatients and outpatients in two double-blind placebo-controlled sequential analyses according to Bross (1952). MCL was given in 5 single doses of 0.7 mg/kg b.w. at 0 h (loading) and at 2 h (i.e. start of chemotherapy) and 6, 10 and 14 h (as maintenance doses). Both studies ended after 8 sequential pairs in favor of MCL (2 alpha = 2 beta = 0.05). Major antiemetic protection (2 emetic episodes per 26 h) was achieved for 8/8 of inpatients and 7/8 of outpatients (placebo 0/8 and 0/8). Side effects neither required discontinuation of the antiemetic regimen nor additional therapy. The median of MCL plasma levels ranged from 150 to 750 ng/ml and terminal half-lives from 3.9 to 8.9 h. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|